Skip to main content

Advertisement

Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Article metrics

  • 651 Accesses

The original article was published in Cardiovascular Diabetology 2018 17:157

Correction to: Cardiovascular Diabetology (2018) 17:157 https://doi.org/10.1186/s12933-018-0800-2

Following publication of the original article [1], based on the authors review, the GLP1 receptor agonists in type 2 diabetes published in Cardiovascular Diabetology, a meta-analysis of GLP-1 and non-GLP-1 based therapies was performed on cardiovascular outcomes. Unfortunately, as the authors later realized, there was an error in the equation used to calculate the relative risks. Instead of subtracting the number of events from the total number of patients in the sample, these values were added which generated a similar increase in all studies. They reframed the analyzes and found small differences, which were relatively proportional to each study. There was no change in the significance of the analyzes; i.e. all data that were initially statistically significant remained significant and vice versa. The changes have been corrected in the new figures (Figs. 1, 2, Additional file 1) presented below. There was no compromise of any of the conclusions of the text and, therefore, no change was made in the manuscript.

Fig. 1
figure1

Forest plots showing the effects of GLP-1- and non-GLP-1-based therapies on a therapies on a MACE, b non-fatal MI

Fig. 2
figure2

Forest plots showing the effects of GLP-1- and non-GLP-1-based therapies on cardiovascular death

Reference

  1. 1.

    Sposito AC, Berwanger O, de Carvalho LSF, Saraiva JFK. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc Diabetol. 2018;17:157. https://doi.org/10.1186/s12933-018-0800-2.

Download references

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author information

Correspondence to Andrei C. Sposito.

Additional files

12933_2019_825_MOESM1_ESM.docx

Additional file 1: Table S1. Risk of Bias of Individual Randomized Controlled Trials. Table S2. Egger Bias Analysis. Table S3. Differences in p-values for all trials combined according to the choice of fixed or random methods. Figure S1. Funnel plots for myocardial infarction. Figure S2. Funnel plots for MACE. Figure S3. Funnel plots for Death due to heart failure. Figure S4. Funnel plots for CV death. Figure S5. Funnel plots for All-cause death.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sposito, A.C., Berwanger, O., Carvalho, L.S.F. et al. Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc Diabetol 18, 23 (2019) doi:10.1186/s12933-019-0825-1

Download citation